

# Information on candidates nominated for election or re-election to the board

## Re election

### Bo Jesper Hansen

Chairman and Board member since 2013. Born 1958. MD. PhD. Other appointments: Chairman of Swedish Orphan Biovitrum AB (publ), and Topotarget A/S. Board member of Hyperion Therapeutics Inc., GenSpera Inc., Newron SA., Ablynx NV., Orphazyme A/S and CMC Kontrast AB. Previous appointments include various positions in Swedish Orphan International AB since 1993, including CEO 1998–2010. Medical advisor for Synthélabo, Pfizer, Pharmacia and Yamanouchi. Founder of Scandinavian Medical Research. No holdings in Karolinska Development.

Independent of the company and its senior management, as well as of major shareholders in the company.

No holdings in Karolinska Development

### Hans Wigzell

Director since 2006. Born 1938. MD and Professor of Immunology. Other appointments: Chairman of Rhenman & Partner Asset Management AB. Board member of Sarepta Pharmaceuticals, SOBI AB, Valneva AS, Cadila Pharmaceuticals Svenska AB and RaySearch Laboratories AB (publ). Member of The Royal Swedish Academy of Engineering Sciences and of the Royal Swedish Academy of Sciences. Previous assignments include, among others, the President of Karolinska Institutet's Nobel Committee, and President of Karolinska Institutet and Director General of the Smittskyddsinstitutet.

Independent of the company and its senior management, as well as of major shareholders in the company.

Holdings in Karolinska Development 8 491 shares, series B.

### Charlotte Edenius

Director since 2012. Born 1958. PhD., Medical Degree. Other appointments: Executive VP Development at Medivir AB. Previous appointments include Senior VP Preclinical & Clinical R&D at Orexo AB, CSO at Biolipox AB, several positions within Clinical R&D at AstraZeneca as well as academic research at Karolinska Institutet and Board Member of Karolinska Institutet Innovations AB and Qlucore AB.

Independent of the company and its senior management, as well as of major shareholders in the company.

No holdings in Karolinska Development.

### **Klaus Wilgenbus**

Director since 2012. Born 1962. MD. Other appointments: Corporate Senior Vice President Business Development / Licensing & Strategy of Boehringer Ingelheim GmbH. Previous appointments include several management positions within Boehringer Ingelheim GmbH, including Senior Vice President Licensing, Vice President R&D Licensing and Director for Exploratory Research in Oncology at Boehringer Ingelheim's R&D Centre in Vienna as well as academic research at Stanford University and the German Cancer Research Centre, Heidelberg.

Independent of the company and its senior management, as well as of major shareholders in the company.

No holdings in Karolinska Development.

### **Vlad Artamonov**

Director since 2012. Born 1978. MBA, B.Sc. Other appointments: Board Member of Redbank Energy Ltd. and of Coastal Capital International Ltd., Managing Partner at Coastal Capital International Ltd. Previous appointments include Investment Analyst at Greenlight Capital Inc. and a position in the Global Merger & Acquisition Group at Merrill Lynch in New York.

Independent of the company and its senior management, as well as of major shareholders in the company.

Holdings in Karolinska Development 3,470,541 shares, series B (by related legal person).

## **New election**

### **Henriette Richter**

Born 1971. PhD, MSc. Other appointments: Investment Director Novo Seeds, Novo A/S. Chairman of Avilex Pharma ApS and Affinicon ApS, Board Member of Orphazyme A/S, EpiTherapeutics A/S, and Board member of the Green Development and Demonstration Program (GUDP) under the Danish Ministry of Food, Agriculture, and Fisheries. Previous appointments: Chairman of Cytoguide ApS, Board member of MycoTeq ApS and Nanofence ApS. Advisory Board member, Department of System Biology, the Danish University of Technical Sciences.

Independent of the company and its senior management, as well as of major shareholders in the company.

No holdings in Karolinska Development.

**Robert Holland**

Born 1955. MD PhD. Other appointments: Board member of Newron Pharmaceuticals SpA and Early Clinical Development Consulting Ltd. Chief Medical Officer and member of the executive team of Oxford Gene Technology IP Ltd. Previously, senior executive positions at AstraZeneca including Head of Personalised Healthcare & Biomarkers and Head of Neuroscience; clinical research roles at Wellcome, Solvay and Upjohn. Fellow of the Faculty of Pharmaceutical Medicine.

Independent of the company and its senior management, as well as of major shareholders in the company.

No holdings in Karolinska Development.

**Carl Johan Sundberg**

Born 1958. Licensed physician and Professor of Physiology. Currently Board director of Cobra Biologics AB, Coordinator Science & Society at the President's office, Head of the Unit for Bioentrepreneurship, Elected member of the Royal Swedish Academy of Engineering Sciences, Member of the International Olympic Committee's Medical Commission, Inspektor (guardian) for the Medical Student's association and Chair of Research!Sweden. Previously Investment director at Karolinska Investment Fund, Board director of Global Genomics AB, Angiogenetics AB, NsGene AS, Cellectricon AB, Alfta Rehab Center Holding AB, Karolinska Education AB and Feelgood Svenska AB, Vice-president of Euroscience and President Swedish Society for Sports Medicine.

Independent of the company and its senior management. Not independent of major shareholders in the company.

No holdings in Karolinska Development.